Page 14 - Read Online

Page 8 of 9 Shimizu et al. Hepatoma Res 2020;6:12 I http://dx.doi.org/10.20517/2394-5079.2019.48

Authors’ contributions
Made substantial contributions to conception and design of the study and performed data analysis and
interpretation: Shimizu T, Tsuchiya K, Kurosaki M
Conceptualization: Shimizu T, Tsuchiya K, Kurosaki M
Methodology: Yasui Y, Hisamatsu T
Data collection: Kirino S, Watakabe K, Osawa L, Okada M, Wang W, Higuchi M, Takaura K, Kaneko S,
Tamaki N, Nakanishi H, Itakura J, Takahashi Y
Writing - original draft preparation: Shimizu T, Tsuchiya K,
Writing - review and editing: Kurosaki M
Supervision: Hisamatsu T, Izumi N

Availability of data and materials
The original raw data used to support the findings of this study have not been made available because of
the risk that will come into conflict with Personal Information Protection Law in Japan.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
This study was approved by the ethical committee at Musashino Red Cross Hospital (approval number
28077).

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
2. Ferlay J, Shin, HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer
2010;127:2893-917.
3. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014;63:844-55.
4. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-92.
5. Toyoda H, Kumada T, Tada T, Mizuno K, Tanaka J, et al. The impact of HCV eradication by direct-acting antivirals on the transition of
precancerous hepatic nodules to HCC: a prospective observational study. Liver Int 2019;39:448-54.
6. Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, et al. Improved detection of focal liver lesions at MR imaging:
multicenter comparison of gadoxetic acid enhanced MR images with intraoperative findings. Radiology 2004;230:266-75.
7. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, et al. The uptake transporter OATP8 expression decreases during multistep
hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011;21:2056-66.
8. Kim HY, Choi JY, Kim CW, Bae SH, Yoon SK, et al. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic
resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis. Liver
Transplant 2012;18:850-7.
9. Kogita S, Imai Y, Okada M, Kim T, Onishi H, et al. Gd-EOB-DTPA enhanced magnetic resonance images of hepatocellular carcinoma:
correlation with histological grading and portal blood flow. Eur Radiol 2010;20:2405-13.
10. Lim KS. Diffusion-weighted MRI of hepatocellular carcinoma in cirrhosis. Clin Radiol 2014;69:1-10.
11. Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan
Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 2019;49:1109-13.
12. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol